Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry-Reference-Cited by-同舟云学术

Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry

Published:2017-10-30 Issue:2 Volume:21 Page:422-430
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Favalli Ennio G.¹^ORCID,Sinigaglia Luigi¹,Becciolini Andrea¹,Grosso Vittorio²,Gorla Roberto³,Bazzani Chiara³,Atzeni Fabiola⁴,Sarzi Puttini Pier C.⁴,Fusaro Enrico⁵,Pellerito Raffaele⁶,Caporali Roberto²

Affiliation:

1. Department of Rheumatology; Gaetano Pini Institute; Milan Italy

2. Department of Rheumatology; University of Pavia; IRCCS Policlinico San Matteo Foundation; Pavia Italy

3. Rheumatology and Immunology Unit; University of Brescia, Spedali Civili; Brescia Italy

4. Rheumatology Unit; University of Milan; L. Sacco Hospital; Milan Italy

5. Department of Rheumatology; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza; Torino Italy

6. Rheumatology Unit; Ospedale Mauriziano; Torino Italy

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1756-185X.13199/fullpdf

Reference39 articles.

1. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis;Aletaha;Ann Rheum Dis,2012

2. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review;Moots;Rheumatology (Oxford),2012

3. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases;Souto;Rheumatology (Oxford),2016

4. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update;Smolen;Ann Rheum Dis,2014

5. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis;Singh;Arthritis Rheumatol,2016

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of patients with inflammatory rheumatic diseases after treatment failure with a first tumour necrosis factor inhibitor: A narrative review;Modern Rheumatology;2023-04-06

2. Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study;RMD Open;2022-11

3. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study;Clinical Rheumatology;2022-05-10

4. Predictive factors for retention of golimumab over a median 4‐year duration in Japanese patients with rheumatoid arthritis in a real‐world setting: A retrospective study and literature review;International Journal of Rheumatic Diseases;2022-01-06

5. Real-world effectiveness and safety of golimumab in rheumatoid arthritis treatment;Journal of the Chinese Medical Association;2021-12-07